Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daxor Posts Net Loss Of $1.5 Million In Q1 2009
Results Of Operations Three months ended March 31, 2009 as compared with three months ended March 31, 2008: Operating Revenues and Expenses For the three months ended March
Results Of Operations Three months ended March 31, 2009 as compared with three months ended March 31, 2008: Operating Revenues and Expenses For the three months ended March
Recent Corporate Highlights: Achieved positive operating cash flow of $0.9 million for the second quarter of 2009 Increased Diagnostic & Biopharmaceutical Products revenue by 23% and BioServices revenue
Excluding interest, depreciation and stock-based compensation on a non-GAAP basis, the Company had net income of $203,698 for the first quarter of 2009 compared to $338,310 for the
Sales in emerging markets represented 26 % of the total of sales recorded in this quarter. Operating charges break down into sales and marketing expenses (EUR1.83 million), general
Investigators for the upcoming Clarification of Optimal Anticoagulation through Genetics Trial (COAG Trial) have selected Osmetech’s Warfarin Sensitivity Tests and eSensor XT-8 molecular diagnostics instrument platform for ten
Swiss biopharmaceutical company Actelion has reported that the Independent Data and Safety Monitoring Board or DSMB has recommended continuation of the pivotal Phase III study BUILD-3, evaluating the
Entellus Medical, a medical technology company, has started enrollment in the FinESS Registry, a prospective, post-approval registry study designed to assess subject rhinosinusitis symptomatic status of up to
US-based Sadra Medical, a developer of new therapies for the treatment of aortic valve disease, has raised $30m in new investment capital. The round was led by Accuitive
In his position at SRI, he also developed technologies for vibration and acoustic control of large-scale systems. “We are pleased to add Gary Guthart to the company’s board,”
Amsterdam Molecular Therapeutics or AMT, a Netherlands-based company engaged in the development of human gene therapy, has initiated treatment of the first patient in a preregistration clinical trial